Find disease awareness content and relevant supporting materials
Inlyta fails Phase III trial as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy .- Pfizer
-Pfizer Inc. has announced that the independent Data Monitoring Committee for the Phase III ATLAS trial evaluating Inlyta (axitinib) as...
Update on CheckMate -914 trial evaluating Opdivo + Yervoy as adjuvant treatment of localized renal cell carcinoma.- BMS
Bristol Myers Squibb announced that Part A of the Phase III CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as an adjuvant treatment for patients with localized renal cell carcinoma (RCC) who have undergone full or partial removal of the kidney and who are at moderate or high risk of relapse, did not meet the primary endpoint of disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR).
CHMP negative against Sutent for the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.- Pfizer.
Pfizer Inc.announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended...